Malaria - Pipeline Review, H1 2020

May 2020 | 394 pages | ID: ME8E977808DEN
Global Markets Direct

Abstracts

Malaria - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malaria – Pipeline Review, H1 2020, provides an overview of the Malaria (Infectious Disease) pipeline landscape.

Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria and pregnant women and their unborn children. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea and vomiting. Treatment includes anti-malarial medicines and healthy lifestyle.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malaria – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Malaria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malaria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Malaria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 2, 15, 15, 55, 23 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 18, 44 and 32 molecules, respectively.

Malaria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Malaria (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Malaria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Malaria (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Malaria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Malaria (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Malaria (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Malaria (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Malaria - Overview
Malaria - Therapeutics Development
Malaria - Therapeutics Assessment
Malaria - Companies Involved in Therapeutics Development
Malaria - Drug Profiles
Malaria - Dormant Projects
Malaria - Discontinued Products
Malaria - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Malaria, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Malaria - Pipeline by 4SC AG, H1 2020
Malaria - Pipeline by AbbVie Inc, H1 2020
Malaria - Pipeline by AdaptVac ApS, H1 2020
Malaria - Pipeline by Akshaya Bio Inc, H1 2020
Malaria - Pipeline by Alfasigma SpA, H1 2020
Malaria - Dormant Projects, H1 2020
Malaria - Discontinued Products, H1 2020
Malaria - Discontinued Products, H1 2020 (Contd..1), H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Malaria, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

4SC AG
AbbVie Inc
AdaptVac ApS
Akshaya Bio Inc
Alfasigma SpA
AliquantumRx Inc
Allergy Therapeutics Plc
Altimmune Inc
Amivas LLC
Artemis Therapeutics Inc
Artificial Cell Technologies Inc
AUM LifeTech Inc
Avalia Immunotherapies Ltd
Bharat Biotech Ltd
Brain-Gen LLC
Bristol-Myers Squibb Co
Cadila Healthcare Ltd
Carna Biosciences Inc
Cascade Therapeutics Inc
CEL-SCI Corp
Cellics Therapeutics Inc
Cesa Alliance SA
Cilian AG
Collaborations Pharmaceuticals Inc
Curevac AG
DesignMedix Inc
DMG Deutsche Malaria GmbH
Eisai Co Ltd
ElSohly Laboratories Inc
EpicentRx Inc
EpiVax Inc
Etna Biotech Srl
Evotec SE
Expres2ion Biotechnologies ApS
Fox Chase Chemical Diversity Center Inc
GeoVax Labs Inc
GlaxoSmithKline Plc
Hawaii Biotech Inc
Ichor Medical Systems Inc
Immtech Pharmaceuticals Inc
Immune Modulation Inc
Imutex Ltd
IMV Inc
Indoco Remedies Ltd
Innovex Therapeutics SL
IPCA Laboratories Ltd
Jacobus Pharmaceutical Co Inc
Kymab Ltd
La Jolla Pharmaceutical Company
LondonPharma Ltd
Lumen Bioscience Inc
Lyndra Inc
MediSynergics LLC
Merck & Co Inc
Merck KGaA
Microbiotix Inc
Mitsubishi Tanabe Pharma Corp
Mycosynthetix Inc
Mymetics Corp
Nobelpharma Co Ltd
Novartis AG
Ocean Biomedical
Osivax SAS
Otsuka Holdings Co Ltd
Pacific Meniuoke Biopharmaceutical Company
Pfizer Inc
Precigen Inc
Protein Potential LLC
Radix Pharmaceuticals Inc
Replikins Ltd
Rodos BioTarget GmbH
Sanaria Inc
Sanofi
Serum Institute of India Ltd
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shin Poong Pharm Co Ltd
Sumitomo Dainippon Pharma Co Ltd
Takeda Pharmaceutical Co Ltd
Theravectys SA
Titan Pharmaceuticals Inc
Vac4All SAS
VLP Biotech Inc
VLP Therapeutics LLC